CT-G32 vs Retatrutide
CT-G32 (also SCO-940) is the first publicly disclosed single molecule built to act on four receptors: GLP-1, GIP, glucagon and amylin. Retatrutide (LY3437943) acts on the first three and has published phase 3 results. CT-G32 has only been tested in animals, with its first data shown in November 2026. This page compares them as research compounds.
| CT-G32 | Retatrutide | |
|---|---|---|
| Development code | CT-G32 (SCO-940) | LY3437943 |
| Receptor targets | GLP-1, GIP, glucagon and amylin (four) | GLP-1, GIP and glucagon (three) |
| Molecule | One molecule acting on all four | One peptide acting on all three |
| Evidence so far | Obese rats and primate blood-level studies, company-reported | Phase 3 trials in people, published |
| Headline result | Numerically greater weight loss than retatrutide in obese rats at the same molar dose | TRIUMPH-1: 17.6% to 25.0% at 80 weeks, placebo 3.9% |
| Status | Preclinical; a US trial application is planned by February 2027 | Phase 3; a US filing is planned for early 2027 |
| Peptx availability | Not available | UK single vials and Factory Direct kits |
- Development code
- CT-G32 (SCO-940)LY3437943
- Receptor targets
- GLP-1, GIP, glucagon and amylin (four)GLP-1, GIP and glucagon (three)
- Molecule
- One molecule acting on all fourOne peptide acting on all three
- Evidence so far
- Obese rats and primate blood-level studies, company-reportedPhase 3 trials in people, published
- Headline result
- Numerically greater weight loss than retatrutide in obese rats at the same molar doseTRIUMPH-1: 17.6% to 25.0% at 80 weeks, placebo 3.9%
- Status
- Preclinical; a US trial application is planned by February 2027Phase 3; a US filing is planned for early 2027
- Peptx availability
- Not availableUK single vials and Factory Direct kits
Three receptors or four
Retatrutide combines activity at the GLP-1 and GIP receptors, the pair tirzepatide acts on, with activity at the glucagon receptor. CT-G32 keeps those three and adds the amylin receptor, the target of cagrilintide, eloralintide and petrelintide.
Amylin is a separate hormone system from the incretins. Until now it has been added as a second molecule alongside an incretin compound, as with cagrilintide and semaglutide, or eloralintide and tirzepatide. CT-G32 is the first disclosed attempt to put amylin and all three of retatrutide's targets into one molecule.
What the first data showed, and what it did not
The first CT-G32 results were presented at the TIDES Europe conference in Amsterdam on 3 to 5 November 2026. In diet-induced obese rats, the developers reported numerically greater weight loss than retatrutide at the same molar dose, a smaller share of the lost weight coming from lean mass, and lower insulin levels. In primates the compound stayed in the blood long enough to support a once-weekly form.
These are company-reported animal results from a conference, not a peer-reviewed paper. No figures or statistical tests were published with the announcement, and "numerically greater" does not mean the difference was shown to be reliable. CT-G32 has not been given to people, so nothing is known about how it is tolerated.
Retatrutide's record is of a different kind. TRIUMPH-1, published in the New England Journal of Medicine in September 2026, enrolled 2,339 adults and reported weight reductions of 17.6%, 23.7% and 25.0% at 80 weeks, against 3.9% on placebo.
Four receptors with two molecules
The same four receptors can be covered in the laboratory today with two separate compounds: retatrutide for GLP-1, GIP and glucagon, and a selective amylin agonist such as eloralintide for the fourth. Peptx supplies the two as single vials and as Retalora, a research blend of Retatrutide 10mg and Eloralintide 2.5mg in one vial.
A blend of two molecules is not a quad agonist, and no published study has tested retatrutide and eloralintide together. The two components can differ in how strongly and for how long each acts, which a single molecule fixes by design.
Bottom line for research labs
CT-G32 is the first single molecule to add amylin to retatrutide's three targets, and its first rat data compared well with retatrutide. It is still an animal-stage candidate with no published figures. Retatrutide remains the multi-receptor reference with phase 3 data. Labs studying what the amylin arm adds to a triple agonist currently work with retatrutide and a separate amylin agonist.